tbuckley/cabot-search huggingface dataset:
Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Authors: Basem M. William, Maribeth Hohenstein, Fausto R. Loberiza, Gabriel C. Caponetti, R. Gregory Bociek, Philip Bierman, James O. Armitage, Wing-Chung Chan, Julie M. Vose
Journal: Blood (2010)
Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial
Authors: James W. Welsh, Steven N. Seyedin, Pamela K. Allen, Wayne L. Hofstetter, Jaffer A. Ajani, Joe Y. Chang, Daniel R. Gomez, Arya Amini, Stephen G. Swisher, Mariela A. Blum, Ahmed I. Younes, Quynh-Nhu Nguyen, Bruce D. Minsky, Jeremy J. Erasmus, Jeffrey H. Lee, Manoop Bhutani, Ritsuko U. Komaki
Journal: Journal of Thoracic Oncology (2016)
David Oliver: Base care on need, not age
Authors: David Oliver
Journal: BMJ (2016)

BerkshireIn 2010 the NHS chief, David Nicholson, proposed a revolution in hospital inpatient care for older (not younger) people, akin to the closure of long stay psychiatric hospitals. 1But hospital admissions of older people continue to rise, and delays in discharge have worsened alongside fewer beds. 2 One recurring policy idea that defies evidence and experience is that most "high need, high cost" 3 older people can be kept away from hospital through lower tech, lower cost community interventions. 4 5 But, in describing inappropriate occupancy of acute beds by these pesky old folk who could hypothetically be cared for elsewhere, 6 7 soundbites are not evidence based solutions.Systematic reviews of evidence for reductions in admissions, bed occupancy, and cost, or for better outcomes resulting from care closer to home, have been far from conclusive. 8 9The most recent promulgator of the idea was the surgeon and former health minister Ara Darzi, who wrote, "We need to keep high cost patients out of hospital." 10His logic?A small percentage of patients account for a high percentage of hospital occupancy and spending.][5][6][7][8][9][10][11][12] Darzi described these patients as "typically older, with multiple chronic conditions" and "costing 400% more than the average."How dare they?Darzi failed to mention that many also have acute illness or injury and rapid decompensation that complicate their frailty, as well as multiple long term conditions requiring an acute response. 13 14He didn't propose keeping younger people away from hospitals in their hour of need. Endemic ageism exists in all health and care settingsThe 2010 Equality Act forbids age discrimination in public services. 15Yet the Centre for Policy on Ageing has found endemic ageism in all health and care settings.
TCT-163 Time to Reperfusion and Infarct Size in Patients With STEMI Undergoing Primary PCI: A Collaborative Patient-Level Pooled Analysis of 10 Randomized Trials
Authors: Gennaro Giustino, Bjorn Redfors, Ulrich Schaefer, Holger Thiele, Manesh Patel, James Udelson, E. Magnus Ohman, Ingo Eitel, Christopher Granger, Akiko Maehara, Ajay Kirtane, Philippe Généreux, Paul Jenkins, Ori Ben-Yehuda, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)
RENTABILIDAD DEL SCREENING DE CÁNCER COLORRECTAL (CCR) EN PACIENTES CANDIDATOS A TRASPLANTE HEPÁTICO (TH) SIN SOSPECHA DE PATOLOGÍA ORGÁNICA DEL COLON
Authors: R Borobia Sánchez, E Martos Vizcaíno, CP De Gracia Fernández, A Caballero Marcos, A Díaz Gómez, L Dieguez Montes, M Romero Cristobal, O Nogales Rincón, MM Salcedo Plaza, C Gonzalez Asanza
Journal: Endoscopy (2016)

Se ha descrito mayor incidencia de adenomas avanzados en pacientes cirróticos respecto a la población general (13,93% vs. 7,66%). La colonoscopia como screening pre-TH pretende detectar lesiones avanzadas que requerirán resección y CCR que contraindicaría el TH. La complejidad clínica asociada a la fragilidad mucosa condicionan la búsqueda de estrategias que minimicen las complicaciones.
TCT-310 Comparative efficacy of drug-eluting stents in chronic total occlusions: A report from the SCAAR
Authors: Truls Råmunddal, Christian Dworeck, Oscar Angeras, Jacob Odenstedt, Dan Ioanes, Göran Olivecrona, Ulf Jensen, Mikael Aasa, Per Albertsson, Elmir Omerovic
Journal: Journal of the American College of Cardiology (2016)
A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph+) Leukemias Including Patients with T315I Mutation
Authors: Jorge E. Cortes, Moshe Talpaz, Hagop M Kantarjian, Hedy Smith, Dale Bixby, Usha Rafferty, Mark S. Berger, Scott C. Wise, Tom J. Rutkoski, Bryan Smith, Richard A. Van Etten
Journal: Blood (2011)
Time to share: lessons from post hoc analyses of IPF trials
Authors: Daniel J Kass, Naftali Kaminski
Journal: Thorax (2016)

It is, perhaps, an embarrassment of riches for idiopathic pulmonary fibrosis (IPF) researchers and providers—the approval of pirfenidone and nintedanib for the treatment of IPF and on its heels, an unprecedented interest on the part of pharmaceutical companies to sponsor clinical trials to test new candidates. In addition, large amounts of clinical data from patients with IPF of very diverse genetic and environmental backgrounds accompanied the clinical trials for pirfenidone and nintedanib. And the new studies promise to yield even more data, repositories of blood, cells, DNA and RNA, at an ever-increasing degree of sophistication. With the availability of these biorepositories and data repositories, very provocative questions can be asked—and potentially answered.

It is in this context that we read in Thorax a new post hoc analysis by Professor Kreuter and colleagues of 624 patients with IPF pooled from the placebo arms of the pirfenidone trials (CAPACITY 004 and 006 and ASCEND).1 The authors have previously analysed these patients and have addressed some intriguing questions, including how anticoagulation and acid suppression in IPF for comorbid conditions affected study outcomes.2 ,3 In the present article, they have turned their attention to another question that has dogged clinical researchers previously, namely how the use of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG coenzyme A) reductase inhibitors, popularly known as ‘statins’, affects outcomes in IPF. The authors employed a shared frailty model, which is an extension of the Cox regression model,1 to determine the effect of statins on study outcomes without adjustment and a multivariate model to adjust for age, …
TCT-349 Five-Year Clinical Outcomes After Stent Implantation for Left Main Coronary Artery From the Multicenter AOI LMCA Stenting Registry
Authors: Masanobu Ohya, Kazushige Kadota, Mamoru Toyofuku, Takeshi Morimoto, Hirooki Higami, Yasushi Fuku, Kyohei Yamaji, Hiromi Muranishi, Yuhei Yamaji, Koji Nishida, Daisuke Furukawa, tomohisa tada, Euihong Ko, Kenji Ando, Hiroki Sakamoto, Takashi Tamura, Kazuya Kawai, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2016)
Response evaluation with endoscopic ultrasound (EUS) measuring maximum tumor thickness to predict pathological response after neoadjuvant chemoradiation therapy (CRT) in patients with locally advanced esophageal cancer (EC)
Authors: C. Jost, J. C. Schuller, C. Meyenberger, P. Bauerfeind, P. Moosmann, J. L. Frossard, R. von Moos, D. Koeberle, U. Metzger, T. Ruhstaller
Journal: Journal of Clinical Oncology (2007)

15009 Background: EUS does not accurately assess T-stage after neoadjuvant CRT due to inflammation, necrosis and fibrosis. We evaluated whether maximum tumor thickness (MTT) can predict pathological response (tumor regression grade, TRG) after CRT. Methods: Patients (pts) with resectable, locally advanced EC, were treated with 2 cycles of docetaxel/cisplatin (DC) q3w followed by CRT (DC weekly x5 with concomitant 45 Gy radiation therapy) and surgery. Radial scan EUS (7.5MHz) measured MTT at baseline and 3–5 weeks after CRT completion. We prospectively hypothesized that MTT =6mm in the second EUS predicts complete and subtotal pathological response (TRG1 and 2), tested by logistic regression. The effect of &gt;50% reduction of MTT was analysed as well. Results: 66 pts from 11 institutions were treated; median age 61y (35–70y); adenocarcinoma (AC) 53%; squamous cell carcinoma 46%; 40 pts were eligible for the EUS project (10 no surgery, 10 tumor stenosis prohibiting EUS, 5 MTT not measured, 1 intolerant to EUS). Initial EUS staging: 9 uT2N1, 3 uT3N0, 27 uT3N1, 1 uT3Nx; Siewert-type-1 in 13 of 22 AC. Reduction of MTT to =6mm correctly predicted TRG1/2 with sensitivity (sens) 45%, specificity (spec) 90%, negative predictive value (NPV) 62%, and positive predictive value (PPV) 82%, the Iogistic regression model showed a trend predicting response only (OR 0.80; C.I. 0.62–1.03; p=0.082). Reduction of MTT &gt;50% predicted TRG1/2 with sens 40%, spec 75%, NPV 56% and PPV 62%. Conclusions: The absolute value of maximum tumor thickness =6mm in the second EUS correctly predicts a good response to CRT in 82% (spec 90%) - rather than the relative reduction of MTT &gt;50% -, but does not identify all responders. Feasibility in this multicenter setting was limited by exclusions due to tumor stenosis and incomplete measurements. [Table: see text] No significant financial relationships to disclose.
Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink
Authors: Blánaid M Hicks, Hui Yin, Oriana H Y Yu, Michael N Pollak, Robert W Platt, Laurent Azoulay
Journal: BMJ (2016)

To determine whether the use of glucagon-like peptide-1 (GLP-1) analogues, compared with the use of dipeptidylpeptidase-4 (DPP-4) inhibitors, is associated with an increased risk of incident breast cancer in patients with type 2 diabetes. Population based cohort study. Clinical Practice Research Datalink, UK. 44 984 women aged at least 40 years, who were newly treated with glucose lowering drugs between 1 January 2007 and 31 March 2015, with follow-up until 31 March 2016. Time varying use of GLP-1 analogues compared with use of DPP-4 inhibitors, with exposures lagged by one year for latency purposes. Time dependent Cox proportional hazards models were used to estimate adjusted hazard ratios with 95% confidence intervals of incident breast cancer associated with use of GLP-1 analogues overall, by cumulative duration of use, and time since initiation. The cohort was followed for a mean of 3.5 years (standard deviation 2.2), with 549 incident events of breast cancer recorded (crude incidence 3.5 (95% confidence interval 3.3 to 3.8) per 1000 person years). Overall, compared with use of DPP-4 inhibitors, use of GLP-1 analogues was not associated with an increased risk of breast cancer (incidence 4.4 v 3.4 per 1000 person years; hazard ratio 1.40 (95% confidence interval 0.91 to 2.16)). Hazard ratios gradually increased with longer durations of use, with a peak between two to three years of GLP-1 use (2.66 (95% confidence interval 1.32 to 5.38)), and returned closer to the null after more than three years of use (0.98 (0.24 to 4.03)). A similar pattern was observed with time since initiation of GLP-1 analogues. In this population based cohort study, use of GLP-1 analogues was not associated with an overall increased risk of breast cancer. Although it is not possible to rule out a tumour promoter effect, the observed duration-response associations are likely the result of a transient increase in detection of breast cancers in GLP-1 analogue users.
Extent of lymphadenectomy and survival in stomach cancer
Authors: S. L. Wong, H. Ji, J. D. Birkmeyer
Journal: Journal of Clinical Oncology (2007)

17008 Background: Based on population-based studies, some investigators have posited that patients undergoing more extensive lymphadenectomy as part of their resection for stomach cancer had improved late survival rates. Such findings have prompted calls for the use of total lymph node counts as a quality indicator for hospitals. However, apparent relationships between number of lymph nodes resected and survival may be confounded by patient selection bias and provider factors. It is not clear that hospitals with higher lymph node counts have better outcomes than other hospitals. The purpose of this study is to examine relationships between total lymph node counts and survival for stomach cancer. Methods: Using the national Surveillance Epidemiology and End Results (SEER)-Medicare linked database (1992–2002), we first identified all patients undergoing major resections for gastric cancer (n=3,049). Hospitals at which the procedures were performed were categorized into 3 groups (terciles) according to the median number of nodes examined. We then assessed 5-year survival rates for each hospital group, adjusting for potentially confounding patient and hospital characteristics. Results: Hospitals with the highest median lymph node counts had slightly higher 5-year survival rates than those with the lowest node counts (31% vs. 28%; unadjusted HR for mortality 0.90, 95% CI 0.81–1.00). Hospitals with higher lymph node counts tended to treat lower risk patients and had lower procedure volumes. Adjusting for these confounding patient and provider characteristics further weakened the apparent relationship between survival and lymph node counts by hospital (adjusted HR, high vs. low hospital tercile, 0.96; 95% CI 0.85–1.09). Conclusions: Apparent relationships between total lymph node counts by hospital and 5-year survival rates after resection for stomach cancer are relatively weak and explained in large part by confounding patient and provider factors. Stronger evidence should be required before moving forward with this metric as a hospital quality indicator. No significant financial relationships to disclose.
Whole Exome Sequencing of Acute Myeloid Leukemia Patients in Korea and Its Comparison with TCGA Results: Dramatic Difference of Genomic Signatures According to Ethnicity
Authors: Youngil Koh, Dae-Yoon Kim, Jeonghwan Yook, Hyunkyung Park, Chan-Soo Lee, Kwang-Sung Ahn, Hyun-Jung Lee, Hyung Lae Kim, Jungsun Jung, Hyo Jung Kim, Hwi-Joong Yoon, Junglim Lee, Inho Kim, Sung-Soo Yoon, Seonyang Park
Journal: Blood (2014)
Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer
Authors: Yue Wang, Kenneth M. K. Mark, Matthew H. Ung, Arminja Kettenbach, Todd Miller, Wei Xu, Wenqing Cheng, Tian Xia, Chao Cheng
Journal: Genome Medicine (2016)

Homologous recombination (HR) is the primary pathway for repairing double-strand DNA breaks implicating in the development of cancer. RNAi-based knockdowns of BRCA1 and RAD51 in this pathway have been performed to investigate the resulting transcriptomic profiles. Here we propose a computational framework to utilize these profiles to calculate a score, named RNA-Interference derived Proliferation Score (RIPS), which reflects cell proliferation ability in individual breast tumors. RIPS is predictive of breast cancer classes, prognosis, genome instability, and neoadjuvant chemosensitivity. This framework directly translates the readout of knockdown experiments into potential clinical applications and generates a robust biomarker in breast cancer.
Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2
Authors: Yoshinori Matsumoto, Jose La Rose, Oliver A. Kent, Melany J. Wagner, Masahiro Narimatsu, Aaron D. Levy, Mitchell H. Omar, Jiefei Tong, Jonathan R. Krieger, Emily Riggs, Yaryna Storozhuk, Julia Pasquale, Manuela Ventura, Behzad Yeganeh, Martin Post, Michael F. Moran, Marc D. Grynpas, Jeffrey L. Wrana, Giulio Superti-Furga, Anthony J. Koleske, Ann Marie Pendergast, Robert Rottapel
Journal: Journal of Clinical Investigation (2016)

Cellular identity in metazoan organisms is frequently established through lineage-specifying transcription factors, which control their own expression through transcriptional positive feedback, while antagonizing the developmental networks of competing lineages. Here, we have uncovered a distinct positive feedback loop that arises from the reciprocal stabilization of the tyrosine kinase ABL and the transcriptional coactivator TAZ. Moreover, we determined that this loop is required for osteoblast differentiation and embryonic skeletal formation. ABL potentiated the assembly and activation of the RUNX2-TAZ master transcription factor complex that is required for osteoblastogenesis, while antagonizing PPARγ-mediated adipogenesis. ABL also enhanced TAZ nuclear localization and the formation of the TAZ-TEAD complex that is required for osteoblast expansion. Last, we have provided genetic data showing that regulation of the ABL-TAZ amplification loop lies downstream of the adaptor protein 3BP2, which is mutated in the craniofacial dysmorphia syndrome cherubism. Our study demonstrates an interplay between ABL and TAZ that controls the mesenchymal maturation program toward the osteoblast lineage and is mechanistically distinct from the established model of lineage-specific maturation.
TCT-439 Increased incidence of revascularization in diabetic patients treated with the ABSORB everolimus-eluting bioresorbable scaffold: 24-months clinical results
Authors: Robin Kraak, Joelle Elias, Deborah Kalkman, Karel Koch, Jose PS. Henriques, Jan Piek, Jan Baan, Marije Vis, Jan Tijssen, Robert de Winter, Joanna Wykrzykowska
Journal: Journal of the American College of Cardiology (2016)
P0540 : The substitution at rt269 in hepatitis B virus polymerase is associated with the multi-drug resistance as a compensatory mutation
Authors: Sung Hyun Ahn, D.H. Kim, B.K. Kim, A.R. Lee, Sang Hoon Ahn, Y.K. Park, E.-S. Park, K.-H. Kim, Y.K. Park, None Sung Hyun Ahn, E.-S. Park, D.H. Kim, A.R. Lee
Journal: Journal of Hepatology (2015)
TCT-531 INTRACORONARY VS. INTRAVENOUS ADENOSINE FOR FRACTIONAL FLOW RESERVE MEASUREMENT: A META-ANALYSIS
Authors: Stefano Rigattieri, Giuseppe Biondi-Zoccai, Alessandro Sciahbasi, Cristian Di RUsso, Maria Cera, Roberto Patrizi, Silvio Fedele, Francesco Pugliese
Journal: Journal of the American College of Cardiology (2016)
TCT-435 Symptomatic evaluation, exercise performance and presence of ischemia in stress echocardiography at two years after implantation of bioresorbable vascular scaffolds and metallic drug-eluting stents. The ESTROFA Ischemia BVS-mDES study
Authors: Jose M. de la Torre Hernandez, Jose Rumoroso, Soledad Ojeda, Salvatore Brugaletta, Jose Domingo Cascon Perez, Cristina Ruisanchez, Joaquin Sanchez Gila, JESSICA ROA-GARRIDO, Helena Tizon Marcos, Hipolito Gutierrez, None mariano larman, Eduardo Pinar Bermudez, Tamara Garcia Camarero, JOSEFRANCISCODIAZ FERNANDEZ, MANUELPAN ALVAREZ-OSORIO, Miren Morillas Bueno, Jose M. Oyonarte, Luis Ruiz Guerrero, Mireia Ble, Ramon Rubio Paton, Roman Arnold, Kattalin Echegaray, Gonzalo De la Morena, Manel Sabate
Journal: Journal of the American College of Cardiology (2016)
Practical Psychology and Psychiatry for Use in Training-Schools for Attendants and Nurses and in Medical Classes, and as a Ready Reference for the Practitioner.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Presentation, Risk Profiles and Outcomes of Chemotherapy without Bone Marrow Transplant in a Cohort of Minority Patients with Acute Lymphoblastic Leukemia from a Public Health Hospital
Authors: Bety Ciobanu, Shylendra B Sreenivasappa, Tracy Smiley, Barbara Yim, Paula Kovarik, Mousami Shah, Rafid Kouz, Samuel Ofori, Margaret Clare Telfer, Rosalind Catchatourian
Journal: Blood (2008)
Higher Percentages of Ring Sideroblasts and SF3B1 Mutations in Patients with AML Correlate with Mutations in TP53 and Adverse Cytogenetics, but Have No Independent Impact on Outcome
Authors: Pedro Martin-Cabrera, Sabine Jeromin, Tamara Alpermann, Karolína Perglerová, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2015)
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine
Authors: Robert S. Wallis
Journal: European Respiratory Journal (2016)

I read with interest the recent article by Tadolini et al. [1] describing QT (ECG Q-T wave interval) prolongation in a patient with extensively drug-resistant tuberculosis (XDR-TB) being treated with both bedaquiline and delamanid. QT prolongation is a recognised safety concern for both these drugs. In a placebo-controlled trial of delamanid in multidrug resistant-TB, QTcF intervals (using the correction for heart rate of Fridericia [2]) increased 12.1 ms more from baseline in delamanid recipients over 6–10 weeks [3]. An increase of similar magnitude was observed in an open-label 24-week trial of bedaquiline, with most of the effect becoming apparent within the first 1–2 weeks [4]. The authors are correct that there is currently no clinical information regarding QT prolongation when these two drugs are co-administered. Clofazimine prolongs the QT interval and can potentiate the QT effects of other MDR-TB drugs <http://ow.ly/70My302XuKm>
TCT-207 Extended validation of a decision tool (DAPT score) in patients randomized to 6 or 12 months dual antiplatelet therapy after percutaneous coronary intervention with predominantly second-generation drug-eluting stents
Authors: Yukinori Harada, Raphaela Lohaus, Katharina Mayer, Roberto Emmer, Jonathan Michel, Roisin Colleran, Daniele Giacoppo, Jens Wiebe, Robert Byrne, Adnan Kastrati, Stefanie Schulz-Schüpke
Journal: Journal of the American College of Cardiology (2016)
Profound Signaling Abnormalities Due to Cytoplasmic Variants of CSF3R in Patients with Myelodysplastic/Myeloproliferative Syndromes Associated with CSF3R Mutations or Mutations of Splicing Factor U2AF1
Authors: Hrishikesh Mehta, Hideki Maskishima, Muneyoshji Futami, Wei-Ming Kao, Bartlomiej P Przychodzen, Chonghui Cheng, Jaroslaw P. Maciejewski, Seth J. Corey
Journal: Blood (2012)
TCT-429 Safety, feasibility and performance of the first 300 everolimus-eluting bioresorbable scaffold PCI in an all-comers population with ischemic heart disease
Authors: Arif Al Nooryani, Wael Elabbassi, Marija Markovic, amit bhatia, Galal Kerfes, Loai Abudaqa, Anoop Mansoor, bassam al baba, Nagwa Abdel Rahman
Journal: Journal of the American College of Cardiology (2016)
TCT-109 Predictive performance of high-sensitivity cardiac troponin I for all-cause death is affected by cut-off value in patients enrolled in chest pain center at emergency department
Authors: Il Park, Jin-Ho Choi, NAMJOON KIM, Young-Do Jeon, Ji-Sun Choi, Jeong Hoon Yang, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Sang Hoon Lee
Journal: Journal of the American College of Cardiology (2016)